Aurinia Pharmaceuticals (AUPH) News Today → Crypto Pioneer Says: “The last crypto bull market has begun.” (From InvestorPlace) (Ad) Free AUPH Stock Alerts $5.76 -0.01 (-0.17%) (As of 05/17/2024 08:53 PM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 16, 2024 | marketbeat.comAurinia Pharmaceuticals (NASDAQ:AUPH) Shares Up 6.2%Aurinia Pharmaceuticals (NASDAQ:AUPH) Trading Up 6.2%May 15, 2024 | marketbeat.comShort Interest in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Declines By 9.9%Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH - Get Free Report) (TSE:AUP) was the recipient of a large decline in short interest in the month of April. As of April 30th, there was short interest totalling 10,260,000 shares, a decline of 9.9% from the April 15th total of 11,390,000 shares. Based on an average daily volume of 2,070,000 shares, the short-interest ratio is presently 5.0 days. Currently, 8.1% of the shares of the company are sold short.May 15, 2024 | americanbankingnews.comAurinia Pharmaceuticals (NASDAQ:AUPH) Stock Passes Below 200-Day Moving Average of $6.98May 15, 2024 | marketbeat.comAurinia Pharmaceuticals (NASDAQ:AUPH) Shares Pass Below Two Hundred Day Moving Average of $6.98Aurinia Pharmaceuticals (NASDAQ:AUPH) Share Price Crosses Below Two Hundred Day Moving Average of $6.98May 14, 2024 | finance.yahoo.comAnalysis Showing LUPKYNIS® is a Cost-Effective Treatment for Lupus Nephritis Presented at National Kidney Foundation’s Spring Clinical Meeting 2024May 14, 2024 | businesswire.comAnalysis Showing LUPKYNIS® is a Cost-Effective Treatment for Lupus Nephritis Presented at National Kidney Foundation's Spring Clinical Meeting 2024May 13, 2024 | stocknews.comTop 4 Pharma Stocks to Consider This MonthMay 9, 2024 | finance.yahoo.comAurinia Presents Data Reinforcing LUPKYNIS® Safety and Efficacy for People with Lupus Nephritis at Congress of Clinical Rheumatology East 2024May 7, 2024 | businesswire.comAurinia Pharmaceuticals Shareholder Urges Board of Directors to Take Action to Enhance Shareholder ValueMay 7, 2024 | businesswire.comAurinia Will Attend 2024 RBC Capital Markets Global Healthcare ConferenceMay 3, 2024 | marketbeat.comAurinia Pharmaceuticals (NASDAQ:AUPH) Stock Rating Upgraded by StockNews.comStockNews.com upgraded shares of Aurinia Pharmaceuticals from a "hold" rating to a "buy" rating in a research note on Friday.May 2, 2024 | seekingalpha.comAurinia Pharmaceuticals Inc. (AUPH) Q1 2024 Earnings Call TranscriptMay 2, 2024 | marketbeat.comAurinia Pharmaceuticals (NASDAQ:AUPH) Shares Gap Up to $5.20Aurinia Pharmaceuticals (NASDAQ:AUPH) Shares Gap Up to $5.20May 2, 2024 | markets.businessinsider.comLeerink Partners Keeps Their Buy Rating on Aurinia Pharmaceuticals (AUPH)May 2, 2024 | businesswire.comAurinia Pharmaceuticals Reports First Quarter 2024 Financial and Operational ResultsMay 1, 2024 | markets.businessinsider.comAurinia Pharmaceuticals is about to announce earnings — here's what Wall Street expectsMay 1, 2024 | businesswire.comAurinia Underscores Enduring Commitment to People Living with Lupus Nephritis Through Innovative Advocacy and Education Initiatives for Lupus Awareness MonthApril 30, 2024 | seekingalpha.comAurinia: Updated Lupkynis Label Should Keep Sales Growth Momentum GoingApril 30, 2024 | businesswire.comThe U.S. Food & Drug Administration (FDA) Approves Updated LUPKYNIS® (voclosporin) Label to include Long-Term Data from the AURORA Clinical ProgramApril 29, 2024 | marketbeat.comAurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Short Interest Down 6.9% in AprilAurinia Pharmaceuticals Inc. (NASDAQ:AUPH - Get Free Report) (TSE:AUP) saw a large decline in short interest during the month of April. As of April 15th, there was short interest totalling 11,390,000 shares, a decline of 6.9% from the March 31st total of 12,240,000 shares. Currently, 8.9% of the company's stock are short sold. Based on an average daily trading volume, of 2,060,000 shares, the short-interest ratio is currently 5.5 days.April 18, 2024 | seekingalpha.comAurinia Pharmaceuticals: Potential For Significant Upside By Year-End 2024April 18, 2024 | marketbeat.comAurinia Pharmaceuticals (NASDAQ:AUPH) Sets New 52-Week Low at $4.82Aurinia Pharmaceuticals (NASDAQ:AUPH) Sets New 12-Month Low at $4.82April 16, 2024 | businesswire.comUPDATE: New Aurinia Presentation Details at the 2024 Bloom Burton & Co. Healthcare Investor ConferenceApril 15, 2024 | businesswire.comAurinia Pharmaceuticals to Release First Quarter Financial and Operational Results on May 2, 2024April 14, 2024 | marketbeat.comShort Interest in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Increases By 14.9%Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH - Get Free Report) (TSE:AUP) was the target of a significant increase in short interest in March. As of March 31st, there was short interest totalling 12,240,000 shares, an increase of 14.9% from the March 15th total of 10,650,000 shares. Based on an average trading volume of 2,340,000 shares, the days-to-cover ratio is currently 5.2 days. Approximately 9.6% of the company's stock are sold short.April 9, 2024 | businesswire.comAurinia Will Attend 2024 Bloom Burton & Co. Healthcare Investor ConferenceApril 9, 2024 | sg.finance.yahoo.comBRIEF-Soilbuild Construction Says Group Awarded New ContractsApril 7, 2024 | finance.yahoo.comWhen Will Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Breakeven?April 1, 2024 | marketbeat.comAurinia Pharmaceuticals (NASDAQ:AUPH) Shares Up 4.6%Aurinia Pharmaceuticals (NASDAQ:AUPH) Shares Up 4.6%March 31, 2024 | marketbeat.comAurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Short Interest Down 12.0% in MarchAurinia Pharmaceuticals Inc. (NASDAQ:AUPH - Get Free Report) (TSE:AUP) was the target of a significant decrease in short interest in the month of March. As of March 15th, there was short interest totalling 10,650,000 shares, a decrease of 12.0% from the February 29th total of 12,100,000 shares. Based on an average daily trading volume, of 2,360,000 shares, the short-interest ratio is presently 4.5 days. Currently, 8.3% of the shares of the company are sold short.March 26, 2024 | marketbeat.comAurinia Pharmaceuticals (NASDAQ:AUPH) Reaches New 12-Month Low at $4.94Aurinia Pharmaceuticals (NASDAQ:AUPH) Sets New 12-Month Low at $4.94March 19, 2024 | marketbeat.comAurinia Pharmaceuticals (NASDAQ:AUPH) Hits New 12-Month Low at $4.96Aurinia Pharmaceuticals (NASDAQ:AUPH) Sets New 1-Year Low at $4.96March 17, 2024 | finance.yahoo.com11 Oversold Biotech Stocks To Buy Right NowMarch 14, 2024 | finance.yahoo.comAUPH Mar 2024 3.000 callMarch 14, 2024 | marketbeat.comAurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Sees Large Decrease in Short InterestAurinia Pharmaceuticals Inc. (NASDAQ:AUPH - Get Free Report) (TSE:AUP) saw a large drop in short interest in the month of February. As of February 29th, there was short interest totalling 12,100,000 shares, a drop of 28.2% from the February 14th total of 16,850,000 shares. Currently, 9.5% of the shares of the stock are short sold. Based on an average daily volume of 2,470,000 shares, the days-to-cover ratio is currently 4.9 days.March 11, 2024 | marketbeat.comAurinia Pharmaceuticals (NASDAQ:AUPH) Reaches New 1-Year Low at $5.34Aurinia Pharmaceuticals (NASDAQ:AUPH) Hits New 12-Month Low at $5.34March 11, 2024 | marketbeat.comTrexquant Investment LP Has $423,000 Stock Position in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)Trexquant Investment LP trimmed its stake in shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH - Free Report) (TSE:AUP) by 83.0% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 54,403 shares of the biMarch 8, 2024 | finance.yahoo.comWe're Not Worried About Aurinia Pharmaceuticals' (NASDAQ:AUPH) Cash BurnMarch 5, 2024 | seekingalpha.comAurinia Pharma: Cheaper Now, But Buyout Hopes DashedMarch 3, 2024 | marketbeat.comShort Interest in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Drops By 9.1%Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH - Get Free Report) (TSE:AUP) saw a significant decline in short interest in February. As of February 15th, there was short interest totalling 16,850,000 shares, a decline of 9.1% from the January 31st total of 18,530,000 shares. Based on an average daily volume of 2,520,000 shares, the days-to-cover ratio is currently 6.7 days. Currently, 13.2% of the company's stock are short sold.March 1, 2024 | markets.businessinsider.comAurinia Pharmaceuticals: Strong Buy Rating Amidst Share Repurchase and Promising LUPKYNIS ProspectsMarch 1, 2024 | marketbeat.comHC Wainwright Reiterates Buy Rating for Aurinia Pharmaceuticals (NASDAQ:AUPH)HC Wainwright reissued a "buy" rating and issued a $13.00 price objective on shares of Aurinia Pharmaceuticals in a research report on Friday.February 29, 2024 | marketbeat.comCantor Fitzgerald Comments on Aurinia Pharmaceuticals Inc.'s FY2024 Earnings (NASDAQ:AUPH)Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH - Free Report) (TSE:AUP) - Equities research analysts at Cantor Fitzgerald dropped their FY2024 earnings per share (EPS) estimates for shares of Aurinia Pharmaceuticals in a research note issued on Monday, February 26th. Cantor Fitzgerald analyst O. BrayeFebruary 29, 2024 | finance.yahoo.comAurinia Receives Exemptive Relief from Canadian Securities Regulators for Share Repurchase ProgramFebruary 28, 2024 | investing.comAurinia Pharmaceuticals Inc (AUPH)February 27, 2024 | businesswire.comAurinia to Participate in Upcoming Investor Healthcare ConferencesFebruary 26, 2024 | finance.yahoo.comAUPH Oct 2024 8.000 callFebruary 23, 2024 | finance.yahoo.comAUPH Jan 2025 15.000 callFebruary 23, 2024 | finance.yahoo.comAUPH Oct 2024 6.000 putFebruary 23, 2024 | marketbeat.comAurinia Pharmaceuticals (NASDAQ:AUPH) PT Lowered to $10.00Cantor Fitzgerald cut their target price on Aurinia Pharmaceuticals from $12.00 to $10.00 and set an "overweight" rating on the stock in a research report on Friday. Get Aurinia Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for AUPH and its competitors with MarketBeat's FREE daily newsletter. Email Address Crypto Pioneer Says: “The last crypto bull market has begun.” (Ad)Right now, there’s over $6 trillion in potential investment money waiting on the sidelines. That means this crypto bull market has a lot more room to run before it comes close to being a bubble. Click here if you’d like to learn more about these five cryptos… AUPH Media Mentions By Week AUPH Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. AUPH News Sentiment▼0.870.42▲Average Medical News Sentiment AUPH News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. AUPH Articles This Week▼72▲AUPH Articles Average Week Get Aurinia Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for AUPH and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: PRTC News PAHC News NRIX News SAGE News NUVB News WVE News COGT News PRAX News IRON News CVAC News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:AUPH) was last updated on 5/20/2024 by MarketBeat.com Staff From Our PartnersThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaElon’s New Device is About to Shock the WorldInvestorPlaceBiden Nomination CANCELED?The Freeport SocietyUrgent Nvidia WarningAltimetryShocking: One AI startup's revenue could surge 4,735%Manward Press"The Biggest Drug Ever" Is ComingBehind the MarketsExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersMost important medical advance in 100 yearsThe Oxford Club Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aurinia Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
